Oclassen Pharmaceuticals Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$135M
Oclassen Pharmaceuticals General Information
Description
Developer of therapeutics in the fields of dermatology and sexually transmitted diseases. The company offers dermatology-related pharmaceutical products for the prevention, diagnosis, and treatment of skin diseases.
Contact Information
Corporate Office
- 100 Pelican Way
- San Rafael, CA 94901
- United States
Corporate Office
- 100 Pelican Way
- San Rafael, CA 94901
- United States
Oclassen Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 27-Feb-1997 | $135M | Completed | Generating Revenue | ||
| 5. IPO | 27-Mar-1992 | Cancelled | Generating Revenue | |||
| 4. Later Stage VC | 01-Jan-1990 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 20-Mar-1989 | Completed | Product Development | |||
| 2. Early Stage VC (Series B) | 03-Sep-1987 | $3.25M | $4.25M | Completed | Generating Revenue | |
| 1. Seed Round | 01-Apr-1986 | $1M | $1M | Completed | Startup |
Oclassen Pharmaceuticals Patents
Oclassen Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-6040298-A | Administering 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-iodouracil, 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-iodocytosine | Inactive | 23-Dec-1992 | ||
| AU-5960794-A | Compositions effective against acyclovir-resistant strains of herpes viruses | Inactive | 23-Dec-1992 | ||
| WO-1994014457-A1 | Compositions effective against acyclovir-resistant strains of herpes viruses | Inactive | 23-Dec-1992 | ||
| JP-H069403-A | Composition for medical treatment of infection and disease caused by b-type hepatitis virus (hbv) | Inactive | 06-Apr-1992 | ||
| EP-0565412-A1 | Compositions containing 5-iodouracil derivatives for the treatment of hepatitis b infections | Inactive | 06-Apr-1992 | A61K31/70 |
Oclassen Pharmaceuticals Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | ||
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Burr, Egan, Deleage | Venture Capital | Minority | ||
| Fairfield Ventures | Venture Capital | Minority | ||
| Horn Ventures Partners | Venture Capital | Minority |
Oclassen Pharmaceuticals FAQs
-
Where is Oclassen Pharmaceuticals headquartered?
Oclassen Pharmaceuticals is headquartered in San Rafael, CA.
-
What industry is Oclassen Pharmaceuticals in?
Oclassen Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Oclassen Pharmaceuticals a private or public company?
Oclassen Pharmaceuticals is a Private company.
-
What is the current valuation of Oclassen Pharmaceuticals?
The current valuation of Oclassen Pharmaceuticals is .
-
What is Oclassen Pharmaceuticals’s current revenue?
The current revenue for Oclassen Pharmaceuticals is .
-
How much funding has Oclassen Pharmaceuticals raised over time?
Oclassen Pharmaceuticals has raised $5.25M.
-
Who are Oclassen Pharmaceuticals’s investors?
3i Group, Bessemer Venture Partners, Burr, Egan, Deleage, Fairfield Ventures, and Horn Ventures Partners are 5 of 7 investors who have invested in Oclassen Pharmaceuticals.
-
When was Oclassen Pharmaceuticals acquired?
Oclassen Pharmaceuticals was acquired on 27-Feb-1997.
-
Who acquired Oclassen Pharmaceuticals?
Oclassen Pharmaceuticals was acquired by Allergan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process